.css-1xsl8rf{width:100%;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;position:relative;overflow:hidden;background:var(--alert-bg);-webkit-padding-start:var(--chakra-space-4);padding-inline-start:var(--chakra-space-4);-webkit-padding-end:var(--chakra-space-4);padding-inline-end:var(--chakra-space-4);padding-top:var(--chakra-space-1);padding-bottom:var(--chakra-space-1);--alert-fg:var(--chakra-colors-orange-600);--alert-bg:var(--chakra-colors-orange-100);font-weight:var(--chakra-fontWeights-semibold);padding-left:var(--chakra-space-4);}.chakra-ui-dark .css-1xsl8rf:not([data-theme]),[data-theme=dark] .css-1xsl8rf:not([data-theme]),.css-1xsl8rf[data-theme=dark]{--alert-fg:var(--chakra-colors-orange-200);--alert-bg:rgba(251, 211, 141, 0.16);}@media screen and (min-width: 48em){.css-1xsl8rf{padding-left:var(--chakra-space-8);}}Please enable Javascript to use all features and improve your user experience.

Cora P. Habicht

Hannover / DE

imusyn GmbH & Co. KG

Engagements

11/09/2024

Poster
P-15-1
Mezagitamab interference in serological testing can be eliminated with anti-CD38 fab fragments
Die Interferenz von Mezagitamab in serologischen Tests kann mit anti-CD38 Fab Fragmenten vermieden werden
Late breaking abstract
10:30 – 11:00 25 Min. 5 Min.
Abstract lecture
FV-0
Elimination of Anti-CD47 drug interference in serological testing by antigen masking
Eliminierung der Interferenz von Anti-CD47-Medikamenten bei serologischen Tests durch Antigen-Maskierung
Late breaking abstract